← BLACKLEDGER Content Feed

Selling • NEUROPHAGE x BLACKLEDGER • 8 min read • 2026-07-30

BLACKLEDGER Selling Watch: ABOS, EVGO, HOOD

BLACKLEDGERMarket ResearchSellingABOSEVGOHOODDNN
BLACKLEDGER Selling public market research update for ABOS, EVGO, HOOD

BLACKLEDGER's latest selling watch update tracks ABOS, EVGO, HOOD, DNN, CLSK, VKTX from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.

Selling Watch Data

The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-07-30T08:00:45.405924+00:00.

Educational Context: How To Use This Page

This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.

ABOS Public Research Bio

Name: Acumen Pharmaceuticals, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Why ABOS Is In This Public Update

Outside Public Headlines / Source Notes

EVGO Public Research Bio

Name: EVgo, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

EVgo, Inc. owns and operates a direct current fast charging network for electric vehicles in the United States. It offers electricity directly to drivers; original equipment manufacturer charging and related services; and commercial charging. The company also provides ancillary services, such as customization of digital applications, charging data integration, access to chargers behind parking lot or garage pay gates, microtargeted advertising, and charging reservations; and hardware, design, and construction services for charging sites, as well as ongoing operations, maintenance, and networking and software integration solutions through eXtend. In addition, it offers PlugShare, such as data, research, and advertising services and equipment procurement and operational services. The company was founded in 2010 and is headquartered in El Segundo, California. EVgo, Inc. operates as a subsidiary of EVgo Holdings LLC.

Why EVGO Is In This Public Update

Outside Public Headlines / Source Notes

HOOD Public Research Bio

Name: Robinhood Markets, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

Robinhood Markets, Inc. operates financial services platform in the United States. The company's platform allows users to invest in stocks, exchange-traded funds (ETFs), and American depository receipts. It offers fractional trading, recurring investments, access to investing on margin, fully-paid securities lending, cash sweep, instant withdrawals, retirement program, around-the-clock trading, joint investing accounts, event contracts, future contract services, and short selling. The company also provides various learning and education solutions comprise Snacks, an accessible digest of business news stories for a new generation of investors; Learn, which is an online collection of guides, feature tutorials, and financial dictionary; Newsfeeds that offer access to free, premium news from sites from various sites, such as Barron's, Reuters, and Dow Jones. In addition, the company offers In-App Education, a resource that covers investing

Why HOOD Is In This Public Update

Outside Public Headlines / Source Notes

DNN Public Research Bio

Name: Denison Mines Corp.. Market class: stock. Public bias: Bear. Public tier: Extended.

Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. It holds 95% interest in its flagship project Wheeler River uranium project located in the Athabasca Basin region in northern Saskatchewan. The company was formerly known as International Uranium Corporation and changed its name to Denison Mines Corp. in December 2006. The company was founded in 1954 and is headquartered in Toronto, Canada.

Why DNN Is In This Public Update

Outside Public Headlines / Source Notes

CLSK Public Research Bio

Name: CleanSpark, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

CleanSpark, Inc. operates as a bitcoin mining company in the Americas. The company owns, leases, and operates data centers and power assets. Its infrastructure supports Bitcoin, a digital commodity. The company was formerly known as Stratean Inc. and changed its name to CleanSpark, Inc. in November 2016. CleanSpark, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.

Why CLSK Is In This Public Update

Outside Public Headlines / Source Notes

VKTX Public Research Bio

Name: Viking Therapeutics, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystr

Why VKTX Is In This Public Update

Outside Public Headlines / Source Notes

What The Public Data Shows

The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.

Why This Category Matters

The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.

Research-Only Notice

BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.

Research-only. No execution signal. Not financial advice.